Adjuvanted H1N1 Vaccine Excites FDA Panel, But Jury Is Still Out

Pending further data on adjuvants from firms and NIH, FDA's Vaccines and Related Biological Products Advisory Committee is comfortable with FDA's plans to license unadjuvanted H1N1 flu vaccines under the strain change process.